TRAIL (TNF Related Apoptosis Inducing Ligand, TNF-related Apoptosis-inducing Ligand TRAIL, Apo 2 Ligand, Apo2 Ligand, Apo-2 Ligand, Apo 2L, Apo2L, Apo-2L, CD253, CD253 Antigen, Protein TRAIL, TL2, Tumor Necrosis Factor (Ligand) Su
Artikelnummer:
USB-T8180-01L-ML550
Hersteller Artikelnummer:
T8180-01L-ML550
Alternativnummer:
USB-T8180-01L-ML550-100
Hersteller:
US Biological
Wirt:
Rabbit
Kategorie:
Antikörper
Applikation:
FLISA, IHC, WB
Immunogen:
Recombinant human CD253.
MaxLight(TM)550 is a new Yellow-Green photostable dye conjugate comparable to Alexa Fluor(TM)546, 555, DyLight(TM)549 , Cy3(TM), TRITC and offers better labeling efficiency, brighter imaging and increased immunodetection. Absorbance (550nm), Emission (575nm), Extinction Coefficient 150,000. Activation of apoptosis by CD253 occurs through binding to the death-signaling receptors DR4 (TRAILR1) and DR5 (TRAILR2), leading to formation of the death-inducing signaling complex (DISC) and the triggering of a proteolytic caspase cascade. There are however decoy receptors known as DcR1 (TRAILR3) and DcR2 (TRAILR4) which competitively bind to CD253 and are unable to initiate apoptosis. CD253 also plays a role in immune surveillance, acting as a mediator of monocyte, NK cell, dendritic cell and T cell anti-tumor and anti-viral cytotoxicity. Applications: Suitable for use in FLISA, Immunohistochemistry (paraffin), and Western Blot. Other applications not tested. Recommended Dilution: Immunohistochemistry (paraffin): 0.25ug/ml FLISA: 0.5ug/ml Western Blot: 0.1-0.2ug/ml Requires antigen retrieval using heat treatment for 20 minutes prior to staining of paraffin sections. Optimal dilutions to be determined by the researcher. Storage and Stability: Store product at 4C in the dark. DO NOT FREEZE! Stable at 4C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight(TM)550 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Note: Applications are based on unconjugated antibody.
